P1 · 10–25 yearsPublished brief
Healthcare / housing / consumer services
The aging of the population is a slow, high-certainty demand driver: the US 65+ population is projected to rise from 58 million (2022) to 82 million by 2050, with the 65+ share of population moving from 17% to 23% (PRB), while older adults overwhelmingly prefer to remain in their own homes. That preference redirects spending toward products and services that extend mobility, sensory function, chronic-disease monitoring and home-based care. The most investable exposures are companies with recurring in-home revenue and disclosed segment economics (e.g., ResMed in-home resupply, hearing pure-plays, orthopedic implant leaders, home-care operators); home-modification and retail names are more diluted, second-order plays. The central risks are administered-price reimbursement (CMS finalized an aggregate ~1.3% cut to Medicare home-health payments for CY2026 and the 2025 reconciliation law is estimated to cut federal Medicaid by ~$911B) and structural caregiver scarcity.
- Researched companies
- 14
- Sourced indicators
- 10
- Cited sources
- 24
Open investment brief →P1 · 3–10 yearsPublished brief
Aerospace / industrial services
Years of under-delivery of new aircraft have pushed the average global fleet age toward thirteen years while backlogs sit at record levels, forcing airlines to keep older aircraft flying and spend heavily on maintenance, spare parts, leased engines and used serviceable material. That scarcity is showing up directly in H1 2026 results across the value chain: GE Aerospace commercial services grew 26%, Safran civil spare parts grew 29.3% in USD, Pratt & Whitney commercial aftermarket grew 19%, and independent players HEICO, TransDigm, AAR, StandardAero, VSE and FTAI all printed double-digit growth with several guidance raises. The theme is investable because certification barriers, engine shop capacity and skilled-labor scarcity make aftermarket supply slow to expand, sustaining pricing power for several years even as new-aircraft deliveries recover. The main caveat is that H1 2026 delivery data show the strongest output since 2018-2019, so the acute-scarcity phase is maturing rather than beginning.
- Researched companies
- 13
- Sourced indicators
- 10
- Cited sources
- 16
Open investment brief →P1 · 5–15 yearsPublished brief
Insurance / municipal finance / adaptation
Physical climate losses are being transmitted into the real economy primarily through insurance repricing and retreat, which in turn pressures property values, mortgage collateral and the property-tax bases that secure a large share of the $4.5 trillion US municipal bond market. Because municipal spreads still show little measurable pricing of this risk while insurance markets are repricing rapidly, demand is rising for property-level risk data, catastrophe modeling, credit analytics and adaptation engineering. The investable expression is the toolmakers and capacity owners in that transmission chain rather than the risk itself.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 24
Open investment brief →P1 · 3–10 yearsPublished brief
Healthcare / manufacturing
Recurring shortages of sterile injectables and essential generics have made reliable, validated manufacturing and containment capacity strategically scarce, and 2025-2026 US policy (an August 2025 API-reserve executive order, BARDA capacity funding, and tariff/tax-credit proposals) is beginning to reward domestic redundancy over lowest-cost supply. The clearest evidence sits with bottleneck suppliers of containment and delivery components (West, Stevanato) and with US-capacity generic injectable makers (Hikma, Amneal), where validated aseptic capacity and quality systems translate into mix, margin and share gains. The case is qualified: a large share of recent supplier growth is GLP-1-linked rather than a pure essential-medicine reliability premium, procurement still frequently buys on lowest price, and a central fill-finish asset (Catalent) is now private and inaccessible to public investors.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 38
Open investment brief →P1 · 5–15 yearsPublished brief
Industrial automation / testing / certification
Every safety-critical asset now being built in greater volume — aircraft, reactors, ships, semiconductors, power equipment — must be measured, inspected and certified before it can be sold or operated, and the capacity to do that is scarcer than the factories themselves. Fetched 2026 evidence shows record orders and backlogs at test-and-measurement suppliers (AMETEK orders +23% in Q1 2026; Teledyne all-time record orders with ~$5.0bn funded backlog in Q2 2026; Curtiss-Wright book-to-bill 1.3x), steady mid-single-digit organic growth with margin expansion across the accredited TIC majors, and a documented shortage of certified inspection labor. The theme offers exposure to recurring, regulation-anchored demand that scales with production volumes but is less cyclical than the capex it verifies. The principal caveats are that aggregate US construction spending has cooled (-1.5% YoY in May 2026) and part of the current order strength is defense- and nuclear-specific rather than broad reindustrialization.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 20
Open investment brief →P1 · 5–15 yearsPublished brief
Defense / shipping / industrial infrastructure
A structural gap between allied naval demand and Western shipbuilding, repair, and marine-equipment capacity is drawing sustained government funding toward domestic yards, dry docks, and component suppliers. The durable opportunity is in the scarce industrial capacity — yards, marine power, castings, and naval components — that must expand before fleets can, rather than in shipping freight cycles.
- Researched companies
- 14
- Sourced indicators
- 5
- Cited sources
- 4
Open investment brief →P1 · 3–10 yearsPublished brief
Healthcare / nuclear medicine
Radiopharmaceutical therapy is scaling from a niche into a multi-billion-dollar oncology modality, evidenced by Novartis Pluvicto reaching US$651M in Q2 2026 net sales (+43% YoY) and pure-plays Telix and Lantheus guiding to roughly US$1.0-1.45B of 2026 revenue. The investable edge sits less in the drug molecule than in a fragile physical supply chain: scarce enriched targets, a handful of reactors/cyclotrons/accelerators, specialized isotope separation, and time-critical logistics for isotopes that decay in days. Because these isotopes cannot be stockpiled and capacity is hard to permit and build, infrastructure, isotope-production and distribution assets can capture durable value alongside drug developers. The thesis is real but early-cycle and capital-intensive, and it is exposed to capacity overbuild, reimbursement risk and single-point supply failures.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 43
Open investment brief →P1 · 5–15 yearsPublished brief
Water / environmental services
PFAS has moved from a filtration niche to a regulated, litigated, multi-decade lifecycle market spanning detection, treatment, waste handling, destruction and long-term monitoring. The core federal drivers survived the 2025-2026 deregulatory review: EPA retained the 4.0 ppt PFOA/PFOS drinking-water limits and the CERCLA hazardous-substance designation, while proposing to stretch compliance to 2031 and rescind standards for four other PFAS. Funding is unusually visible for an environmental theme - litigation settlements (3M alone up to $12.5B through 2036) plus federal infrastructure money - and scarce permitted assets (accredited labs, selective media, RCRA incineration, Subtitle C disposal) sit in the hands of a small set of listed companies.
- Researched companies
- 12
- Sourced indicators
- 9
- Cited sources
- 64
Open investment brief →P1 · 3–10 yearsPublished brief
Critical infrastructure / aerospace / defense
Analyst synthesis: verified evidence shows increasing aviation GNSS interference, an EASA/IATA mitigation plan, an FCC complementary-PNT inquiry, Department of Transportation field tests, MGUE deployment and awards, and current anti-jam, resilient-navigation, retrofit and alternative-signal products. These facts establish activity, not investability, market size, pricing power or financial materiality; company selection still requires direct segment and valuation evidence.
- Researched companies
- 12
- Sourced indicators
- 12
- Cited sources
- 28
Open investment brief →P1 · 5–15 yearsPublished brief
Grid / industrial manufacturing
A multi-year collision of new electricity load (AI/data centers, electrification) and aging-grid replacement is meeting structurally constrained transformer, switchgear and electrical-steel manufacturing, producing multi-year backlogs, record book-to-bill ratios and sharply higher equipment prices. Fetched 2026 disclosures show grid-equipment OEMs (GE Vernova, Siemens Energy Grid Technologies, Eaton, Powell) posting order and backlog growth well above revenue, while the transformer-core material (grain-oriented electrical steel) has a single US producer (Cleveland-Cliffs). The theme may be investable through capacity-constrained OEMs and scarce-material suppliers that currently command pricing power and unusually long revenue visibility. The central swing factor, and the main thesis break, is whether roughly USD 1.8bn of announced North American capacity (arriving 2027-2028) plus global expansions eventually outpaces demand.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 13
Open investment brief →P1 · 3–10 yearsPublished brief
Telecommunications / energy / maritime security
AI, cloud and electrification are driving relentless growth in subsea data and power infrastructure at a moment when the vessels, robotics, sensors and crews needed to install, monitor and repair it are concentrated and aging. Repeated Baltic-Sea cable damage and new EU/NATO/ITU resilience mandates are converting 'invisible' undersea assets into a funded strategic priority. Owners of the scarce bottleneck assets are seeing multi-year backlog visibility and margin expansion. The theme is investable, but exposure quality varies sharply between near-pure cable-makers and diversified conglomerates whose undersea revenue is small and undisclosed.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 39
Open investment brief →P1 · 5–15 yearsPublished brief
Healthcare / diagnostics / care delivery
Historically underdiagnosed and under-reimbursed women's health conditions are being converted into defined, coverage-backed care categories by a convergent policy, clinical-evidence and reimbursement shift dated to 2025-2026. The most direct listed exposure sits in fertility benefits (Progyny), fertility/women's-health devices and consumables (CooperCompanies' CooperSurgical), and women's diagnostics and imaging (Hologic), where recurring, reimbursement-linked revenue is already visible. The theme is investable primarily through differentiated players with proprietary assets and employer/payer distribution; for many large mapped incumbents women's health is a minority of revenue, so the case is selective rather than broad-basket.
- Researched companies
- 13
- Sourced indicators
- 8
- Cited sources
- 12
Open investment brief →P2 · 5–15 yearsPublished brief
Energy / oilfield services
Enhanced geothermal systems (EGS) are moving from pilots to bankable commercial projects as shale-era oilfield techniques (horizontal drilling, multi-stage stimulation, real-time subsurface modeling) collapse drilling costs and de-risk reservoirs. Field results in 2024-2026 (Utah FORGE drilling speeds up over 500%, Fervo per-well costs down from $9.4M to $4.8M) plus durable US tax credits through 2033 have unlocked non-recourse project finance and multi-gigawatt offtake. That opens a new, potentially large demand pool for subsurface service providers, EGS developers and surface-power equipment makers. The case is real but early: it hinges on cost curves continuing and reservoir performance holding at scale, and geothermal remains immaterial to the diversified majors most exposed to it.
- Researched companies
- 12
- Sourced indicators
- 11
- Cited sources
- 18
Open investment brief →P2 · 5–15 yearsPublished brief
Agriculture / logistics / climate resilience
The theme sells volatility reduction rather than commodity price prediction: irrigation, resilient genetics, crop protection, input efficiency, storage and cold chain earn recurring demand whenever weather, input or logistics shocks recur. 2026 evidence shows structural volatility persisting even in a record-supply year — a Strait of Hormuz blockage spiked urea prices (Yara, 2026-07-17), sulfur costs forced Mosaic to curtail phosphate output (2026-05-11), and FAO vegetable oil prices ran +23.3% year-over-year in June 2026 while the headline index was flat. Meanwhile North American farm-level capital spending is at a cyclical trough (Deere Production & Precision Ag sales -14% y/y; Lindsay North America irrigation -11% y/y), which suppresses near-term revenue for resilience providers but creates a potentially attractive entry window into a 5-15 year structural demand story — provided the investor accepts that the adoption thesis is partly cyclical and currently under pressure.
- Researched companies
- 14
- Sourced indicators
- 10
- Cited sources
- 18
Open investment brief →P2 · 5–15 yearsPublished brief
Industrial efficiency / process equipment
Industrial heat is roughly two-thirds of industrial energy demand, and the IEA projects industrial heat demand to grow 14% (+16 EJ) over 2025-2030, with renewable electricity supplying nearly 80% of the growth in annual industrial heat consumption - implying a multi-year retrofit and electrification cycle in heat recovery, steam systems, thermal management and process controls. In Europe, structurally elevated industrial gas prices (EUR 0.0605/kWh for non-household consumers in H2 2025) plus the CBAM definitive regime that started 1 January 2026 create measurable cost incentives for efficiency capex. Mid-2026 company evidence shows record order books at the listed suppliers of this equipment (Alfa Laval, Trane, ABB, Johnson Controls), though a material share of that momentum is currently driven by data-center cooling rather than classic industrial heat-recovery retrofits - a distinction the theme's monitoring must keep separating.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 20
Open investment brief →P2 · 3–10 yearsPublished brief
HVAC / environmental regulation
The AIM Act's binding HFC phase-down (85% below baseline by 2036) plus the EPA Emissions Reduction and Reclamation (ER&R) rule convert environmental regulation into recurring, largely non-discretionary demand for recovery, reclamation, leak detection and low-GWP replacement equipment across a large installed cooling base. Because virgin HFC supply is contractually capped and steps down sharply (consumption allowances fall from 181.5M MTEVe in 2026-2028 to 90.8M in 2029-2033), reclaimed refrigerant and the low-GWP chemistry replacing legacy gas gain structural scarcity value. Early transmission is visible: reclaimed HFC volumes rose ~30% in 2024, Hudson realized HFC pricing near $6/lb in Q1 2026, and Chemours' low-GWP Opteon franchise grew double digits. Investability is uneven — pure-play reclaimers and refrigerant-chemical franchises show the cleanest exposure, while diversified HVAC OEMs capture the conversion cycle but dilute the reclamation-specific economics.
- Researched companies
- 12
- Sourced indicators
- 10
- Cited sources
- 41
Open investment brief →P2 · 3–10 yearsPublished brief
Financial infrastructure / settlement
Tokenization is moving from speculative crypto into regulated settlement, collateral, and liquidity management, with tokenized US Treasuries and real-world assets scaling rapidly through incumbent custodians, exchanges, and post-trade infrastructure. The durable opportunity is in the regulated rails — custody, settlement, and post-trade infrastructure — that institutions must use, rather than in tokens themselves.
- Researched companies
- 14
- Sourced indicators
- 5
- Cited sources
- 4
Open investment brief →P2 · 5–15 yearsPublished brief
Water / circular economy
A converging regulatory stack is turning wastewater treatment from a disposal cost into a regulated driver of water reuse, nutrient/energy recovery and advanced treatment: the revised EU Urban Wastewater Treatment Directive (EU) 2024/3019 mandates energy neutrality and phosphorus recovery; California (effective 1 Oct 2024) and Colorado now permit direct potable reuse; EPA released Water Reuse Action Plan 2.0 on 16 April 2026; and EPA's January 2025 draft PFAS-in-biosolids risk assessment raises the cost of the status-quo land-application model. Third-party estimates put the broader water recycle/reuse market near USD 17.9bn in 2025 growing roughly 10% annually to about USD 30bn by 2030. The most defensible exposure is 'picks-and-shovels' - treatment systems, water chemicals, measurement/analytics and energy-recovery devices with recurring aftermarket, consumable and SaaS pull-through - rather than the still-immature markets for recovered nutrients and reclaimed-water offtake. The theme is early and diffuse: every mapped public company is diversified, so theme-pure exposure cannot be isolated from disclosures and adoption depends on multi-year utility procurement cycles.
- Researched companies
- 12
- Sourced indicators
- 11
- Cited sources
- 16
Open investment brief →